Mologic partners with FINDdx for schistosomiasis rapid test

By |2021-05-14T11:34:14+01:00May 13th, 2021|

Mologic and Neglected Diseases Bedfordshire, UK, May 13 2021: Neglected Tropical Diseases affect more than one billion people worldwide, in some of the poorest areas. According to the World Health Organisation, schistosomiasis is a disease of poverty that leads to chronic ill health and affects nearly 240m [...]

Mologic’s COVID-19 Rapid Antigen Self-Test Selected by NIH for RADx Initiative Funding

By |2021-05-20T11:52:08+01:00April 6th, 2021|

Supported by US initiative to accelerate development and manufacturing including regulatory guidance Advanced diagnostic technology and fully integrated proprietary design requires no specialist training and can be performed at home Bedfordshire, UK, 06 April 2021: Mologic, a leading developer of lateral flow and rapid diagnostic technologies, today announced its [...]

Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test

By |2021-05-20T12:04:32+01:00March 17th, 2021|

York and Bedfordshire, UK, 17 March 2021: Aptamer Group, the developer of diagnostic and therapeutic Optimer reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests. The partnership will work towards CE marking of Aptamer Group’s AptaDx SARS-CoV-2 lateral [...]

Avacta and Mologic announce commercial partnership

By |2021-05-20T12:02:51+01:00February 8th, 2021|

Partnership to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries Cambridge & Wetherby and Bedfordshire, UK, 8th February 2021: Avacta Group plc (AIM: AVCT) (“Avacta”), the developer of Affimer® biotherapeutics and reagents, and Mologic Ltd (“Mologic”) today announced [...]

Mologic Receives CE Mark Approval for Professional-Use COVID-19 Rapid Antigen Test

By |2021-05-20T12:04:19+01:00December 24th, 2020|

Preliminary results show 92% sensitivity and 100% specificity, compared with RT-PCR Bedfordshire, UK, 24 December 2020: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, is pleased to announce its professional-use COVID-19 Rapid Antigen Test has been certified with a CE mark, following independent assessment by [...]

Mologic and the University of Liverpool collaborate to develop a rapid diagnostic test for common agricultural parasite

By |2021-05-20T12:05:09+01:00December 15th, 2020|

Test will enable diagnosis of liver fluke exposure in livestock in 10 minutes, to target treatment, prevent drug resistance and reduce costly production losses Bedfordshire, UK, 15 December 2020: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, today announced it is in the final developmental [...]

Mologic launches rapid diagnostic test for fungal crop pathogen Botrytis

By |2021-05-14T14:27:17+01:00October 8th, 2020|

BotrytisAlert harnesses Mologic’s expert lateral flow technology to enable earlier disease intervention and prevent wide-spread crop failures Developed with funding from Innovate UK as part of the Company’s wider crop protection diagnostic portfolio   Bedfordshire, UK, 8th October 2020: Mologic Ltd, a leading developer of lateral flow and rapid [...]

Mologic Covid-19 Testing at Heathrow Airport

By |2021-05-20T12:01:56+01:00August 29th, 2020|

Mark Davis, CEO, Mologic: “Our involvement in Heathrow Airport’s trial for rapid point of care COVID-19 testing solutions is an exciting, and necessary, step towards getting the UK safely travelling again. As experts in lateral flow technology, our Antigen Test is designed to provide results in 10 minutes, supporting [...]

Mologic CE Marks professional-use rapid diagnostic test for COVID-19 and begins manufacture

By |2021-05-20T11:57:58+01:00June 3rd, 2020|

Mologic is pleased to announce that, following successful independent validation by the Liverpool School of Tropical Medicine (LSTM) and St George’s, University of London, our professional-use rapid diagnostic test for COVID-19 has been certified with a CE mark and is ready for manufacture and global distribution. The “triple antibody” [...]

Preliminary clinical performance data for professional use COVID-19 rapid diagnostic test

By |2021-05-20T11:50:00+01:00May 1st, 2020|

Mologic is pleased to announce that following rigorous independent assessment by St George’s, University London and Liverpool School of Tropical Medicine, our point-of-need, professional use, rapid diagnostic test (RDT) for COVID-19 has achieved preliminary clinical performance data of 98% sensitivity at days 14-21 and specificity of 96%. The test [...]

Go to Top